Senti Biosciences (NASDAQ:SNTI) Stock Rating Upgraded by Wall Street Zen

Senti Biosciences (NASDAQ:SNTI) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Monday.

A number of other brokerages have also recently weighed in on SNTI. Chardan Capital restated a “buy” rating and set a $12.00 price objective on shares of Senti Biosciences in a research note on Friday, August 8th. Laidlaw started coverage on Senti Biosciences in a research report on Friday, June 6th. They set a “buy” rating and a $5.00 target price on the stock.

Senti Biosciences Price Performance

Shares of NASDAQ SNTI opened at $1.52 on Monday. The stock has a market capitalization of $39.76 million, a P/E ratio of -0.17 and a beta of 2.07. Senti Biosciences has a 1-year low of $1.46 and a 1-year high of $16.94. The business has a fifty day moving average price of $2.07 and a 200 day moving average price of $3.03.

Senti Biosciences (NASDAQ:SNTI) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.02. The company had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $1.30 million. As a group, equities research analysts anticipate that Senti Biosciences will post -14.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Armistice Capital LLC acquired a new position in shares of Senti Biosciences in the second quarter valued at about $1,883,000. Nantahala Capital Management LLC acquired a new position in shares of Senti Biosciences in the first quarter valued at about $2,984,000. Heights Capital Management Inc. acquired a new position in shares of Senti Biosciences in the first quarter valued at about $2,520,000. Geode Capital Management LLC increased its holdings in shares of Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after purchasing an additional 117,588 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Senti Biosciences in the fourth quarter valued at about $181,000. 25.73% of the stock is owned by institutional investors and hedge funds.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.